Life Science Giant Danaher Warns Of Sales Decline In 2024; S

Life Science Giant Danaher Warns Of Sales Decline In 2024; Says 'Pandemic Has Transitioned To An Endemic State' Life Science Giant Danaher Stock Is Trading Higher Today - What's Going On? - Danaher (NYSE:DHR)

Danaher reported Q4 2023 adjusted EPS of $2.09, exceeding consensus of $1.89. Sales decreased 10% Y/Y to $6.4B. Non-GAAP core revenue declined 11.5%. Guidance for core revenue growth will continue, but not for base business core revenue.

Related Keywords

Rainer Blair , Life Sciences , Danaher Corp , Cepheid , Chief Executive Officer , Goldman Sachs Downgrades Danaher , Says There , Shift Towards Pharmaceutical ,